


The level of von Willebrand factor is a pronostic marker in patients with metastatic melanoma treated by immune checkpoint inhibitors
The level of von Willebrand factor is a pronostic marker in patients with metastatic melanoma treated by immune checkpoint inhibitors Immunotherapy; Melanoma; Translational Medical Research; Tumor Microenvironment. Laura Keller- Team SIGNATHER : Cell Signalling,...
Fighting bronchial cancers
Fighting bronchial cancers As part of the “No Smoking Month 2022”, the Toulouse Cancer Health Foundation presents the project led by Olivier Calvayrac, CNRS research fellow and Pr Julien Mazières, Head of the Pneumology Department at the Toulouse...
The Roland Garigou Foundation for Culture & Health awards several prizes and grants to the CRCT in 2022
The Roland Garigou Foundation for Culture & Health awards several prizes and grants to the CRCT in 2022 The Fonroga Foundation supports initiatives and achievements in the fields of culture and health in the Toulouse region. On 15 November 2022 it awarded several...
Design of an intracellularly acting antibody blocking the RHOA family of proteins to study a cellular process involved in carcinogenesis.
Design of an intracellularly acting antibody blocking the RHOA family of proteins to study a cellular process involved in carcinogenesis. RHOA-GTPase tripartite split-GFP nanobodies RHO-ROCK signaling single domain antibody (sdAb) Laura Keller- Equipe SIGNATHER : Cell...